TY - JOUR T1 - Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancer JO - Endocrinología y Nutrición (English Edition) T2 - AU - Riesco-Eizaguirre,Garcilaso AU - Galofré,Juan Carlos AU - Grande,Enrique AU - Zafón Llopis,Carles AU - Ramón y Cajal Asensio,Teresa AU - Navarro González,Elena AU - Jiménez-Fonseca,Paula AU - Santamaría Sandi,Javier AU - Gómez Sáez,José Manuel AU - Capdevila,Jaume SN - 21735093 M3 - 10.1016/j.endoen.2015.08.012 DO - 10.1016/j.endoen.2015.08.012 UR - https://www.elsevier.es/en-revista-endocrinologia-nutricion-english-edition--412-articulo-spanish-consensus-for-management-patients-S2173509316300198 AB - BackgroundApproximately one third of the patients with differentiated thyroid cancer (DTC) who develop structurally-evident metastatic disease are refractory to radioactive iodine (RAI). Most deaths from thyroid cancer occur in these patients. The main objective of this consensus is to address the most controversial aspects of management of these patients. MethodsOn behalf of the Spanish Society of Endocrinology & Nutrition (SEEN) and the Spanish Group for Orphan and Infrequent Tumors (GETHI), the Spanish Task Force for Thyroid Cancer, consisting of endocrinologists and oncologists, reviewed the relevant literature and prepared a series of clinically relevant questions related to management of advanced RAI-refractory DTC. ResultsTen clinically relevant questions were identified by the task force. In answering to these 10 questions, the task force included recommendations regarding the best definition of refractoriness; the best therapeutic options including watchful waiting, local therapies, and systemic therapy (e.g. kinase inhibitors), when sodium iodide symporter (NIS) restoration may be expected; and how recent advances in molecular biology have increased our understanding of the disease. ConclusionsIn response to our appointment as a task force by the SEEN and GHETI, we developed a consensus to help in clinical management of patients with advanced RAI-refractory DTC. We think that this consensus will provide helpful and current recommendations that will help patients with this disorder to get optimal medical care. ER -